Compare ANGI & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANGI | LBRX |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.9M | 602.6M |
| IPO Year | 2017 | N/A |
| Metric | ANGI | LBRX |
|---|---|---|
| Price | $8.42 | $24.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $17.00 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 1.2M | 146.3K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1242.86 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $736,386,000.00 | N/A |
| Revenue This Year | $3.64 | N/A |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | ★ 47.60 | N/A |
| 52 Week Low | $1.51 | $13.40 |
| 52 Week High | $19.42 | $24.95 |
| Indicator | ANGI | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.83 | 58.62 |
| Support Level | $7.74 | $22.90 |
| Resistance Level | $8.17 | $24.42 |
| Average True Range (ATR) | 0.60 | 1.47 |
| MACD | -0.39 | 0.02 |
| Stochastic Oscillator | 8.38 | 82.56 |
Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.